本页面由Tiger Trade Technology Pte. Ltd.提供服务

Compugen医疗

2.62
-0.0350-1.32%
盘后2.620.0050+0.19%19:30 EDT
成交量:44.72万
成交额:119.60万
市值:2.47亿
市盈率:7.00
高:2.77
开:2.64
低:2.61
收:2.65
52周最高:3.24
52周最低:1.30
股本:9,455.41万
流通股本:9,245.75万
量比:1.32
换手率:0.48%
股息:- -
股息率:- -
每股收益(TTM):0.3733
每股收益(LYR):0.3783
净资产收益率:50.64%
总资产收益率:15.46%
市净率:2.79
市盈率(LYR):6.91

数据加载中...

2026/04/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/02

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/04

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/05

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/08/23

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2023/08/23

SEC问询函

Form CORRESP - Correspondence
2023/06/23

SEC问询函

Form CORRESP - Correspondence
2023/04/14

SEC问询函

Form CORRESP - Correspondence
2023/02/28

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/03

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/08/04

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/28

[修订]年度报告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/28

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]